The ABIGAIL study was a randomized phase II study of abemaciclib plus ET with or without a short course of induction paclitaxel in patients with previously untreated HR-positive/HER2-negative advanced breast cancer with aggressive disease criteria (18). This evidence concerns the gene ERBB2 and breast carcinoma.